This issue chosen by the Editor of Intestinal Research is the subpopulation analysis of phase 3 induction and maintenance studies about the efficacy and safety of the Ustekinumab for Crohn's disease (CD) performed by Toshifumi Hibi et al. The phase 3 ustekinumab study about the moderate to severe CD was performed previously. It is comprised of two 8-week induction studies (UNITI-1 and UNITI-2) and 44-week randomized maintenance study (IM-UNITI). In this previous study, intravenous ustekinumab had an effect of remission induction and remission maintenance in patients who had a clinical response to induction therapy. This issue reported the efficacy and safety of ustekinumab from the UNITI-1, UNITI-2, and IM-UNITI global studies in a Japanese subpopulation. For Japanese patients, ustekinumab was also effective as induction and maintenance treatments. Read more about the efficacy and safety of ustekinumab in CD. In addition to these articles, read other articles about biologic therapy in patients with CD. Best regards,